Truist initiated coverage on Viatris with a new price target
$VTRS
Biotechnology: Pharmaceutical Preparations
Health Care
Truist initiated coverage of Viatris with a rating of Buy and set a new price target of $15.00
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/9/2025 | $15.00 | Overweight | Barclays |
| 10/15/2025 | $15.00 | Buy | Truist |
| 6/6/2025 | $10.00 | Neutral | Goldman |
| 7/19/2024 | $15.00 | Buy | Jefferies |
| 10/23/2023 | $13.00 → $9.00 | Neutral → Underperform | BofA Securities |
| 6/23/2023 | $11.00 | Equal Weight → Underweight | Barclays |
| 4/24/2023 | $11.00 | Overweight → Equal Weight | Barclays |
| 2/17/2023 | $16.00 → $14.00 | Outperform → Market Perform | BMO Capital Markets |
8-K - Viatris Inc (0001792044) (Filer)
8-K - Viatris Inc (0001792044) (Filer)
8-K/A - Viatris Inc (0001792044) (Filer)
Barclays initiated coverage of Viatris with a rating of Overweight and set a new price target of $15.00
Truist initiated coverage of Viatris with a rating of Buy and set a new price target of $15.00
Goldman initiated coverage of Viatris with a rating of Neutral and set a new price target of $10.00
Receives U.S. Food and Drug Administration (FDA) Approval for Generic Version of Sandostatin® LAR Depot (Octreotide Acetate for Injectable Suspension)U.S. FDA Accepts New Drug Application for Low Dose Estrogen Weekly Patch for ContraceptionU.S. FDA Clears Investigational New Drug Application for MR-146 in Neurotrophic KeratopathyJapan Pharmaceuticals and Medical Devices Agency Accepts Japanese New Drug Application Filing for Pitolisant in Obstructive Sleep Apnea SyndromePITTSBURGH, Dec. 18, 2025 /PRNewswire/ -- Viatris Inc. (NASDAQ:VTRS), a global healthcare company, today announced four recent regulatory milestones spanning across all stages of its global pipeline: Octreotide Acetate for In
PITTSBURGH, Dec. 17, 2025 /PRNewswire/ -- Viatris Inc. (NASDAQ:VTRS), a global healthcare company, today announced that the Company will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on Tuesday, Jan. 13, 2026. The Company's presentation and fireside chat will begin at 9 a.m. PT / 12 p.m. ET. A live webcast of the event can be found at investor.viatris.com. An archived version of the presentation will be available following the live event and can be accessed at the same location for a limited time. About Viatris Viatris Inc. (NASDAQ:VTRS) is a
ETOBICOKE, ON, Dec. 15, 2025 /CNW/ -- Viatris Inc. (NASDAQ:VTRS) has been named one of the 2025 Best Workplaces™ in Ontario and one of the 2025 Best Workplaces™ for Giving Back in Canada. These recognitions highlight Viatris in Canada's commitment to fostering a culture where colleagues are enthusiastic about the work they do, feel valued, engaged and motivated. It is also important to Viatris that we seek out meaningful opportunities to give back. The organization received these recognitions after a thorough and independent analysis conducted by Great Place to Work®. The 2025 Best Workplaces™ in Ontario list is based on direct feedback from employees of the hundreds of organizations that we
4 - Viatris Inc (0001792044) (Issuer)
4 - Viatris Inc (0001792044) (Issuer)
3 - Viatris Inc (0001792044) (Issuer)
4 - Viatris Inc (0001792044) (Issuer)
4 - Viatris Inc (0001792044) (Issuer)
4 - Viatris Inc (0001792044) (Issuer)
PITTSBURGH, Aug. 19, 2025 /PRNewswire/ -- Viatris Inc. (NASDAQ:VTRS), a global healthcare company, today announced the appointment of Andrew Enrietti as Chief Administrative and Transformation Officer. In this newly created role, Enrietti will oversee the company's Human Relations, Business Transformation, Information Technology, Information Security, Global Transportation and Security, and Global Workplaces and Real Estate functions. The consolidation of these areas centralizes leadership of the company's digital, cultural and structural transformation initiatives and is designed to accelerate the company's ongoing strategic evolution.
PITTSBURGH, Aug. 5, 2025 /PRNewswire/ -- Viatris Inc. (NASDAQ:VTRS), a global healthcare company, today announced that David Simmons has been appointed as the newest member of Viatris' Board of Directors. Simmons has deep pharmaceutical industry experience, as well as extensive executive, board, and capital markets expertise. Prior to his current role as CEO of Caliber Holdings Corporation, Simmons served as Operating Partner of Hellman & Friedman, LLC, a leading private equity firm, as well as Chairman and CEO of PPD, Inc., a global contract pharmaceutical research organizati
PITTSBURGH, April 14, 2025 /PRNewswire/ -- Viatris Inc. (NASDAQ:VTRS) today announced that Hemanth J. Varghese has joined the Company as Chief Strategy Officer. Varghese will be a member of the Company's Executive Leadership Team. Varghese is an accomplished healthcare leader with more than 20 years of strategy, operations and corporate development experience. He brings broad experience leading growth initiatives and strategic transformations in diversified multi-national healthcare companies. Prior to joining Viatris, Varghese was President and Chief Operating Officer at Venu
PITTSBURGH, Nov. 4, 2025 /PRNewswire/ -- Viatris Inc. (NASDAQ:VTRS) today announced that on November 3, 2025, its Board of Directors declared a quarterly dividend of $0.12 per share for each issued and outstanding share of the Company's common stock. The dividend is payable on December 15, 2025, to shareholders of record as of the close of business on November 24, 2025. About Viatris Viatris Inc. (NASDAQ:VTRS) is a global healthcare company uniquely positioned to bridge the traditional divide between generics and brands, combining the best of both to more holistically address healthcare needs globally. With a mission to empower people worldwide to live healthier at every stage of life, we pr
PITTSBURGH, Oct. 1, 2025 /PRNewswire/ -- Viatris Inc. (NASDAQ:VTRS) will report third quarter 2025 financial results on Thursday, November 6, 2025. Company executives will host a webcast at 8:30 a.m. ET on the same date to discuss the results. Investors and the general public are invited to listen to a live webcast of the call at investor.viatris.com or by calling 844.308.3344 or 412.317.1896 for international callers. A replay of the webcast also will be available on the website. About ViatrisViatris Inc. (NASDAQ:VTRS) is a global healthcare company uniquely positioned to bridge the traditional divide between generics and brands, combining the best of both to more holistically address healt
Delivers Total Revenues Above Expectations Reflecting the Strength of our Execution and the Resilience of our Diversified Global BusinessPositive Results From Five Phase 3 Data Readouts This Year Reinforce Continued Momentum of Late-Stage Pipeline Returns More Than $630 Million of Capital to Shareholders Year-to-Date Including $350 Million in Share BuybacksReiterates 2025 Financial Guidance Ranges Across all Metrics and Expects to be in the Top Half of the Range for Total Revenues and Adjusted EPS [1]PITTSBURGH, Aug. 7, 2025 /PRNewswire/ -- Viatris Inc. (NASDAQ:VTRS) today reported strong second quarter 2025 financial results and reiterated its 2025 financial guidance ranges across all metri
SC 13G/A - Viatris Inc (0001792044) (Subject)
SC 13G/A - Viatris Inc (0001792044) (Subject)
SC 13G - Viatris Inc (0001792044) (Subject)